Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPARGroundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / M ...
CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 ---- Advancing four clinical programs for ...
Anecdotal evidence has long suggested that sleep problems are especially common for people with Moebius syndrome. Now, a new ...
Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.
Black Americans are more willing to participate in medical studies led by Black doctors and researchers, perceiving them as ...
Treatment-emergent adverse events (TEAEs) occurred in a similar proportion of patients in each group, and were mostly mild or ...
REHOVOT, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: ...
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the ...
This came after Hetero Labs presented the BE study protocol, vide no. AZBE112405, Version No. 01, Dated 15.11.2024 and the ...
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...
The expansion aims to enhance access to clinical studies and reinforce the island’s position as a hub for biomedical research. #NewsismyBusiness ...
A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback